Increasing surgical procedures, trauma, and chronic illnesses are driving blood transfusion demand. This is really crucial. The increased demand for blood components requires effective diagnostic tools to assure safe and compatible blood transfusions.
Technology innovations shape market dynamics. Diagnostic accuracy and efficiency have improved due to blood type, cross-matching, and nucleic acid testing advances. Continuous improvements enabled these advances. Because of this, blood transfusions are safer, which has driven industry expansion.
The industry is affected by strict blood safety and transfusion regulations. Thus, the industry is heavily influenced. As a need, blood transfusion diagnostics companies must follow rules. This is because regulatory limits affect product development, testing, and marketing plans for new markets.
A regular supply of donors is needed to ensure safe blood availability. An increased and diversified blood supply due to blood donation and awareness initiatives has increased the need for sophisticated diagnostics to match and screen blood. The more diversified blood supply has caused this.
Standardized worldwide blood transfusion diagnoses are needed as healthcare systems become more interconnected. Because of this predisposition, uniform testing methodologies have been created, allowing market participants to create widely accepted solutions.
Globally, hemophilia and anemia are on the increase. This has increased the need for reliable blood transfusion testing to assure compatibility and minimize adverse reactions. Thus, market dynamics have been affected.
Molecular diagnostics for blood transfusion recipient compatibility is becoming industry-wide. Due to its high sensitivity in identifying viral infections, nucleic acid testing (NAT) has become widespread. This has improved blood safety and modified customer desires.
It is crucial to have high-quality, reliable diagnostics for blood transfusions. Quality assurance and standardization initiatives in the industry shape the competitive climate and testing process acceptability. These activities set the competitive scene.
Diagnostic firms and healthcare institutions or blood banks are forming more relationships, which is projected to continue. These agreements simplify diagnosis, improve blood transfusion services, and foster market innovation.
Affordability is a major issue in healthcare systems with budgetary constraints. To meet the unique economic landscapes in different regions, market participants are developing precise and competitive diagnostic solutions. This is done to fulfill economic requirements.
Study objectives: Main objective of this research is to provide information about Blood Transfusion Diagnostics market, product, technology and end users.
Key Players
Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Immucor (U.S), Siemens Healthineers (Germany), Ortho Clinical Diagnostics, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Novartis AG (Switzerland), Beckman Coulter, Inc. (U.S.), Ortho Clinical Diagnostics (U.S), Beckman Coulter (U.S), Diagast (France), Abbott Diagnostics (U.S), BAG healthcare (Germany), DiaSorin (Italy), Fujirebio (Belgium), Grifols (Spain), Quidel (U.S), Hologic/Gen-Probe (U.S), Biokit (Spain).
The report for Blood Transfusion Diagnostics market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions
Blood Transfusion Diagnostics market has been segmented on the basis of blood product including Red Blood Cells, Platelets, Plasma, Albumin, Immunoglobulin Preparations and other products. On the basis of technology, the market is segmented into Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test and other technologies. ELISA is further segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassay (CI). Nucleic Acid Amplification is segmented into Thermomechanical analysis (TMA) and real-time PCR. End users are hospitals, clinics, blood banks, laboratories.
Globally, Blood Transfusion Diagnostics market consists of four regions Americas, Europe, Asia Pacific and Middle East and Africa. America is the largest market whose growth is attributed to an increase in the use of nucleic acid amplification test and large number of awareness programs conducted by the government bodies and non-government organizations. Europe is the second largest market. Asia Pacific is showing positive growth this market. The market shows steady growth in Middle East & Africa.
Recent Development
Ortho Clinical Diagnostics introduced the ORTHO VISION Swift and ORTHO VISION Max Swift analyzers in April 2021. These analyzers provide laboratory networks with more processing power and enhanced data security. Hemanext, a blood storage technology company, said in September 2021 that it would raise USD 15 million in a new series A fundraising round and USD 100 million from private equity. Its goal is to spread the Hemanext One System's processes all over the world. The technology has a CE designation, which means it can be sold throughout Europe.
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)